SEARCH

SEARCH BY CITATION

Footnotes

  • 1
    N.M. Nour. An Introduction to Maternal Mortality. Reviews in Obstetrics and Gynecology 2008; 1: 7781; World Health Organisation. 2012. Maternal Mortality Fact Sheet No: 348. Available at: http://www.who.int/mediacentre/factsheets/fs348/en/index.html# [Accessed 20 Sept 2013].
  • 2
    United Nations. 2010. Millenium Development Goals Report 2010.
  • 3
    K.S. Khan, et al. WHO analysis of causes of maternal death: a systematic review. The Lancet 2006; 367: 10661074.
  • 4
    World Health Organisation. Maternal and Perinatel Health. Available at: http://www.who.int/reproductivehealth/topics/maternal_perinatal/epidemiology/en/ [Accessed 20 Sept 2013].
  • 5
    United Nations, op. cit. note 2.
  • 6
    S. Naicker, et al. Shortage of Healthcare Workers in Developing Countries – Africa. Ethnicity and Disease 2009; 19: S1.60164; UNFPA. 2003. Maternal Mortality Update 2002: A Focus on Emergency Obstetric Care.
  • 7
    World Health Organisation. 2012. Trends in Maternal Mortality: 1990 to 2010. WHO, UNICEF, UNFPA and The World Bank estimates.
  • 8
    Z. Alfirevic & A. Weeks. Oral misoprostol for induction of labour. Cochrane Database of Systematic Reviews 2010; G.J. Hofmeyr, A.M. Gulmezoglu & C. Pileggi. Vaginal misoprostol for cervical ripening and induction of labour. Cochrane Database of Systematic Reviews 2010; E. Krause, et al. Off-label use of misoprostol for labor induction: a nation-wide survey in Switzerland. European Journal of Obstetrics & Gynecology and Reproductive Biology 2011; 159: 324328.
  • 9
    H. von Hertzen, et al. Comparison of vaginal and sublingual misoprostol for second trimester abortion: randomized controlled equivalence trial. Human Reproduction 2009; 34: 106112; J. Chai, et al. A randomized trial to compare two dosing intervals of misoprostol following mifepristone administration in second trimester medical abortion. Human Reproduction 2009; 24: 320324.
  • 10
    G.J. Hofmeyr, et al. Misoprostol to prevent and treat postpartum haemorrhage: a systematic review and meta-analysis of maternal deaths and dose-related effects. Bull World Health Organ 2009; 87: 666677; J. Blum, et al. Treatment of post-partum haemorrhage with sublingual misoprostol versus oxytocin in women receiving prophylactic oxytocin: a double-blind, randomised, non-inferiority trial. The Lancet 2010; 375: 217223; B. Winikoff, et al. Treatment of post-partum haemorrhage with sublingual misoprostol versus oxytocin in women not exposed to oxytocin during labour: a double-blind, randomised, non-inferiority trial. The Lancet 2010; 375: 210216.
  • 11
    W.L. Cowman, et al. Vaginal misoprostol aids in difficult intrauterine contraceptive removal: a report of three cases. Contraception 2012; 83: 281284; K. Cepni, et al. Randomised trial of oral misoprostol treatment for cervical ripening before tandem application in cervix cancer. International Journal of Radition Oncology, Biology and Physics 2011; 81: 778781; N.P. Polyzos, et al. Misoprostol prior to hysteroscopy in premenopausal and postmenopausal women. A systematic review and meta-analysis. Human Reproduction Update 2012; 18: 393404.
  • 12
    M. Potts, N. Prata & N.N. Sahin-Hodoglugil. Maternal mortality: one death every 7 min. The Lancet 2010; 375: 17621763.
  • 13
    Winikoff, et al. op. cit. note 10.
  • 14
    O.T. Oladapo, et al. Advance misoprostol distribution for preventing and treating postpartum haemorrhage. Cochrane Database of Systematic Reviews 2012; C.S. Chu, P. Brhlikova & A.M. Pollock. Rethinking WHO guidance: a review of evidence for misoprostol use in the prevention of postpartum haemorrhage. Journal of the Royal Society of Medicine 2012; 105: 336347.
  • 15
    C. Ronsmans & W. Huang. Community based interventions to reduce maternal mortality. The Lancet 2010; 375: 457; M. Potts, et al. Empowering women to control post-partum haemorrhage. The Lancet 2010; 375: 459460.
  • 16
    A.M. Gulmezoglu, et al. Misoprostol use in the community to reduce maternal deaths. The Lancet 2010; 376: 955; FIGO. 2012. Misoprostol for PPH in low resource settings initiative. Available at: http://www.figo.org/projects/figo-misoprostol-post-partum-haemorrhage-low-resource-settings-initiative [Accessed 20 Sept 2013].
  • 17
    Ibid.
  • 18
    World Health Organisation. 2010. Clarifying WHO position on misoprostol use in the community to reduce maternal death. Available at: http://whqlibdoc.who.int/hq/2010/WHO_RHR_10.11_eng.pdf [Accessed 20 Sept 2013].
  • 19
    World Health Organisation. 2013. Essential Medicines Selection. Available at: http://www.who.int/selection_medicines/committees/expert/19/applications/en/ [Accessed 20 Sept 2013].
  • 20
    J.M. Morse. 1994. ‘Emerging from the data’: The cognitive processes of analysis in qualitative inquiry. In Critical issues in qualitative research methods. J.M. Morse, ed. ThousandOaks: Sage.
  • 21
    K. Charmaz. 2006. Constructing grounded theory: a practical guide through qualitative analysis. London: Sage.
  • 22
    S.L. Schensul, J.J. Schensul & M.D. LeCompte. 1999. Essential Ethnographic Methods. Oxford: Altamira Press.
  • 23
    Ronsmans & Huang, op. cit. note 15.
  • 24
    Gulmezoglu, et al. op. cit. note 16, p. 955.
  • 25
    R. Khan & S. Sharma. Use of misoprostol in third stage of labour. The Lancet 2002; 359: 708709.
  • 26
    A. Weeks. Oral misoprostol for postpartum haemorrhage. The Lancet 2006; 368: 2123.
  • 27
    Blum, et al. op. cit. note 10; N. Deole & A. Weeks. Knowledge of correct dosages of misoprostol in reproductive health. International Journal of Gynecology and Obstetrics 2010; 109: 7177.
  • 28
    M. Potts, et al. op. cit. note 15; P.D. Darney. Misoprostol: a book to safe motherhood … or not? The Lancet 2001; 358: 682.
  • 29
    M. Potts, et al. op. cit. note 12.
  • 30
    M. Potts, N. Prata & N.N. Sahin-Hodoglugil. Misoprostol use in the community to reduce maternal death. The Lancet 2010; 376: 955956.
  • 31
    M. Potts, et al. op. cit. note 12.
  • 32
    Ibid: 1763.
  • 33
    M. Potts, et al. op. cit. note 15.
  • 34
    L.G. Cuervo & M. Clarke. Balancing benefits and harms in health care: we need to get better evidence about harms. British Medical Journal 2003; 327: 6566: 66.
  • 35
    World Health Organisation, op. cit. note 18, p. 2.
  • 36
    Aristotle. 1980. Book VI. In Nicomachean Ethics. Oxford University Press.
  • 37
    W.B. Gallie. Essentially Contested Concepts. Preceedings of the Aristotelian Society, New Series 1956; 56: 167198.
  • 38
    Ronsmans & Huang, op. cit. note 15.
  • 39
    K. Kastenhofer. Risk assessment of emerging technologies and post-normal science. Science, Technology & Human Values 2011; 36: 307333.
  • 40
    J. Blocher. Public Discourse, Expert Knowledge, and the Press. Washington Law Review 2012; 97: 409443; E. Volokh. The Trouble With “Public Discourse” as a Limitation on Free Speech Rights. Virginia Law Review 2011; 97: 567594.
  • 41
    J. Habermas. 1991. The Structural Transformation of the Public Sphere. Cambridge, Massachusetts: The MIT Press: 144.
  • 42
    G. Mooney. 2012. The Health of Nations: Towards A New Political Economy. London: Zed Books.
  • 43
    J. Habermas. 1990. Moral Consciousness and Communicative Action. Cambridge: Polity Press.